Chimeric Therapeutics CEO Jennifer Chow joined Steve Darling from Proactive to share news the company has updated their CLTX CAR T trial which has just completed its 2nd dose level. Chow telling Proactive the company saw continued positive safety signals in the 2nd dose cohort. The CLTX CAR T was generally well tolerated with no dose-limiting toxicities. The company is now enrolling patients in dose level 3.
Chimeric Therapeutics sees strong data for 2nd dose cohort in CLTX Car T trial
